Black Diamond Therapeutics Inc (BDTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.12+0.95%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Black Diamond is advancing its tumor-agnostic therapies with positive lung cancer data. The company aims to maintain cash to fund operations into 2028 with $118.3 million as of 2026-Q1. Recent earnings beats show some operational progress. The stock is cheap compared to peers with potential upside if trials succeed.
The company is unprofitable with declining cash reserves and recent earnings misses. Litigation and trial setbacks pose risks. Analysts expect continued losses and no revenue growth next year. The recent sharp selloff reflects these challenges and elevated risk.
The market prices in a turnaround with significant risks, reflected by a 42% drawdown and implied negative growth over 3-5 years. Our fair value of $12.01 suggests some upside, but the stock remains speculative given unprofitable status and uncertain trial outcomes.
Breaks if: cash falls below $100 million before H2 2028
Ensure cash, cash equivalents, and investments are sufficient to fund operating expenses and capital expenditures into the second half of 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is focused on advancing its clinical programs while managing cash burn, but faces risks from market conditions and execution quality.
The current valuation suggests that the market views BDTX as relatively cheap compared to its peers. There is a low expectations gap, indicating that investors are not overly optimistic about future performance.
Management has shown stability in their priorities, particularly in advancing clinical trials and maintaining cash runway. Recent financial performance has been neutral, with a slight decline in cash reserves, but the company is managing expenses effectively.
The thesis hinges on BDTX's ability to execute on its clinical development plans and manage cash effectively. Additionally, broader market conditions, such as sector performance and economic indicators, will significantly impact the company's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: failure to advance FDA approval or negative Phase 3 results by end 2027
Breaks if: EPS loss worsens beyond -$1.0 per share by 2028
Over the next 1 to 3 years, BDTX's performance will depend on its clinical advancements and market dynamics. Not investment advice.